Lennar Corp/ US5260571048 /
13/06/2024 22:10:00 | Var. +0.04 | Volume | Denaro02:00:00 | Lettera02:00:00 | Capitalizzazione di mercato | Dividend Y. | Rapporto P/E |
---|---|---|---|---|---|---|---|
155.04USD | +0.03% | 2.08 mill. Fatturato: 207.25 mill. |
153.18Quantità in denaro: 100 | 155.75Quantità in lettera: 100 | 37.99 bill.USD | 0.97% | 11.29 |
GlobeNewswire
09:01
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients ...
GlobeNewswire
09:00
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investi...
GlobeNewswire
09:00
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patie...
GlobeNewswire
09:00
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimila...
GlobeNewswire
08:00
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ T...
GlobeNewswire
07:00
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EH...
GlobeNewswire
07:00
WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its N...